Skip to content

301230.SZ

PharmaResources (Shanghai) Co., Ltd

SZSE · M 科研服务 · CN

CNY 33.84
−5.26%
Ask drillr

Year over year

Reported trailing growth

Revenue
+18.5%
EBITDA
EBIT
+238.0%
EPS
+81.6%
Free cash flow
+512.8%
Operating cash flow
+139.8%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+12.9%
EBITDA
+0.6%
EBIT
-26.8%
Net income
-20.1%
EPS
-31.9%
Free cash flow
+423.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026